EyePoint Pharmaceuticals (STU:PV3B) Total Equity : €244.22 Mil (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is EyePoint Pharmaceuticals Total Equity?

EyePoint Pharmaceuticals's total equity for the quarter that ended in Dec. 2023 was €244.22 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

EyePoint Pharmaceuticals Total Equity Historical Data

The historical data trend for EyePoint Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Total Equity Chart

EyePoint Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Equity

Get a 7-Day Free Trial

7.50

15.24

163.18

90.97

244.22

EyePoint Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Equity	Get a 7-Day Free Trial															90.97	73.22	52.85	54.93	244.22

EyePoint Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

EyePoint Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2023 )	-	Total Liabilities(Q: Dec. 2023 )
	=	325.704	-	81.486
	=	244.22

EyePoint Pharmaceuticals's Total Equity for the quarter that ended in Dec. 2023 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2023 )	-	Total Liabilities(Q: Dec. 2023 )
	=	325.704	-	81.486
	=	244.22

EyePoint Pharmaceuticals Total Equity Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals (STU:PV3B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3B) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

EYPT:USA

Address

480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (STU:PV3B) Headlines

No Headlines